Reference : Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and v...
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/76020
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
English
Jerusalem, Guy mailto [Université de Liège - ULg > > Oncologie médicale >]
Fasolo, Angelica [> >]
Dieras, Véronique [> >]
Cardoso, Fatima [> >]
Bergh, Jonas [> >]
Vittori, Luc [> >]
Zhang, Yufen [> >]
Massacesi, Cristian [> >]
Sahmoud, Tarek [> >]
Gianni, Luca [> >]
Jan-2011
Breast Cancer Research and Treatment
Kluwer Academic Publishers
125
2
447-455
Yes (verified by ORBi)
International
0167-6806
Dordrecht
The Netherlands
[en] mTOR ; everolimus ; trastuzumab ; vinorelbine ; phase I ; HER2-overexpressing metastatic breast cancer ; oncology
Researchers ; Professionals
http://hdl.handle.net/2268/76020

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Phase I trial of oral mTOR inhibitor.pdfPublisher postprint733.8 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.